264 related articles for article (PubMed ID: 19417639)
1. Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target.
Packard CJ
Curr Opin Cardiol; 2009 Jul; 24(4):358-63. PubMed ID: 19417639
[TBL] [Abstract][Full Text] [Related]
2. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
3. Utility of Lp-PLA2 in lipid-lowering therapy.
Racherla S; Arora R
Am J Ther; 2012 Mar; 19(2):115-20. PubMed ID: 20634673
[TBL] [Abstract][Full Text] [Related]
4. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z
Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606
[TBL] [Abstract][Full Text] [Related]
5. [Lipoprotein associated phospholipase A2].
Rubinstein A; Izkhakov E
Harefuah; 2011 Feb; 150(2):136-40, 205. PubMed ID: 22164942
[TBL] [Abstract][Full Text] [Related]
6. Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease.
Riley RF; Corson MA
IDrugs; 2009 Oct; 12(10):648-55. PubMed ID: 19790016
[TBL] [Abstract][Full Text] [Related]
7. Editorial: why inhibition of lipoprotein-associated phospholipase A2 has the potential to improve patient outcomes.
White H
Curr Opin Cardiol; 2010 Jul; 25(4):299-301. PubMed ID: 20485161
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein-associated phospholipase A(2) and atherosclerosis.
Wilensky RL; Macphee CH
Curr Opin Lipidol; 2009 Oct; 20(5):415-20. PubMed ID: 19667981
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention.
Anderson JL
Am J Cardiol; 2008 Jun; 101(12A):23F-33F. PubMed ID: 18549868
[TBL] [Abstract][Full Text] [Related]
10. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque.
Serruys PW; García-García HM; Buszman P; Erne P; Verheye S; Aschermann M; Duckers H; Bleie O; Dudek D; Bøtker HE; von Birgelen C; D'Amico D; Hutchinson T; Zambanini A; Mastik F; van Es GA; van der Steen AF; Vince DG; Ganz P; Hamm CW; Wijns W; Zalewski A;
Circulation; 2008 Sep; 118(11):1172-82. PubMed ID: 18765397
[TBL] [Abstract][Full Text] [Related]
11. Phospholipase A2 inhibitors.
Garcia-Garcia HM; Serruys PW
Curr Opin Lipidol; 2009 Aug; 20(4):327-32. PubMed ID: 19550325
[TBL] [Abstract][Full Text] [Related]
12. Darapladib.
Bui QT; Wilensky RL
Expert Opin Investig Drugs; 2010 Jan; 19(1):161-8. PubMed ID: 20001561
[TBL] [Abstract][Full Text] [Related]
13. [Lipoprotein-associated phospholipase A(2) and stroke].
Alvarez-Pérez FJ; Verde I
Rev Neurol; 2009 Jul 16-31; 49(2):88-94. PubMed ID: 19598138
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target.
Carlquist JF; Muhlestein JB; Anderson JL
Expert Rev Mol Diagn; 2007 Sep; 7(5):511-7. PubMed ID: 17892360
[TBL] [Abstract][Full Text] [Related]
15. Chronic inhibition of lipoprotein-associated phospholipase A
Prasad M; Lennon R; Barsness GW; Prasad A; Gulati R; Lerman LO; Lerman A
Int J Cardiol; 2018 Feb; 253():7-13. PubMed ID: 29306475
[TBL] [Abstract][Full Text] [Related]
16. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
Sabatine MS; Morrow DA; O'Donoghue M; Jablonksi KA; Rice MM; Solomon S; Rosenberg Y; Domanski MJ; Hsia J;
Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2463-9. PubMed ID: 17766330
[TBL] [Abstract][Full Text] [Related]
17. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.
Kiechl S; Willeit J; Mayr M; Viehweider B; Oberhollenzer M; Kronenberg F; Wiedermann CJ; Oberthaler S; Xu Q; Witztum JL; Tsimikas S
Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1788-95. PubMed ID: 17541022
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein-associated phospholipase A2: an independent predictor of cardiovascular risk and a novel target for immunomodulation therapy.
Khakpour H; Frishman WH
Cardiol Rev; 2009; 17(5):222-9. PubMed ID: 19690473
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein-associated phospholipase A2.
McConnell JP; Hoefner DM
Clin Lab Med; 2006 Sep; 26(3):679-97, vii. PubMed ID: 16938590
[TBL] [Abstract][Full Text] [Related]
20. Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis.
Zhang J; Xu DL; Liu XB; Bi SJ; Zhao T; Sui SJ; Ji XP; Lu QH
Yonsei Med J; 2016 Mar; 57(2):321-7. PubMed ID: 26847282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
